Parts of the Social Democratic Party (SPD) are advocating for the pharmaceutical industry in the face of the planned Statutory Health Insurance (GKV) Contribution Stabilization Law. According to the newspaper Handelsblatt, the party’s health policy spokesman in the Bundestag faction, Christos Pantazis, and his deputy, Matthias Mieves, have published a policy paper arguing that the regulation of the industry must give greater weight to domestic investments, research, and production. The two SPD politicians stress that Germany cannot afford to lose investments, either economically or geopolitically, describing the pharmaceutical sector as a future industry, a research engine, and strategic infrastructure. Their paper is titled: “We are making the pharmaceutical industry a champions’ industry – or it moves away.”
This initiative arrives at a critical juncture when the federal government intends to save billions of euros for statutory health insurance providers through the proposed stabilization law. This regulation also includes provisions for higher manufacturer discounts and tighter pricing rules for innovative medicines. Nevertheless, the industry has been resisting these plans for several weeks. Significant commitments are already being reduced, with the U.S. pharmaceutical giant Eli Lilly announcing a substantial cut to its planned €2.3 billion investment in Rhineland-Palatinate, and Boehringer Ingelheim cancelling investments exceeding €900 million.
SPD health policy expert Pantazis demanded that “anyone who conducts research, produces, and creates jobs in Germany makes a concrete social contribution – and that must be tangibly beneficial in the form of manufacturer discounts.” Furthermore, Pantazis and Mieves are increasing pressure during the government’s pharmaceutical dialogue, with Mieves writing that the conversation cannot merely remain a discussion group. He insisted that Chancellor Merz and Economy Minister Reiche must do everything possible to retain these investments within Germany, arguing that the dialogue format must yield palpable results to restore public trust.
This push is expected to intensify the debate surrounding the contribution stabilization law. More recent information obtained by the newspaper indicates that the finances of statutory health insurance funds are deteriorating faster than anticipated. A spokesperson for the Federal Ministry of Health clarified that this latest financial development must be taken into account during the further parliamentary process.
